Expected to receive approximately 2.025 billion yen in dividends from consolidated subsidiaries. The amount is expected to be recorded as sales in the individual financial statements for the 2027 April period, with no impact on the consolidated performance.
As of April 30, 2026, the controlling shareholder is Mr. Takafumi Suzuki with 10.32% ownership, and a combined total of 69.02%. The company generally does not engage in transactions, clearly stating its policy to protect minority shareholders.
There has been a correction to the consolidated results for fiscal year 2026, with operating cash flow increasing by ¥131.8 billion and cash and cash equivalents being revised to ¥2,028 million. Financial activities also increased, indicating improvements in funding and repayment status.
Plans a cash dividend of 15 yen per share (total dividend of 61 million yen, effective date 2026/07/24), with a simultaneous proposal for amendment of articles of incorporation (scope of business addition and certain deletions) at the Ordinary General Meeting of Shareholders scheduled for July 23, 2026.
Reflection of extraordinary gains of 97,214 thousand yen and extraordinary losses of 292,513 thousand yen in the earnings press release. As part of a portfolio review including the sale of healthcare facilities, the classification of costs was moved from some operating costs to extraordinary losses, keeping total expenses unchanged and positively impacting net income. Reflected in the FY2026 April earnings...
For the fiscal year ending April 2026, net sales were 18.358 billion yen, operating income 119.17 million yen, and net income attributable to owners of the parent of 50.03 million yen, a substantial increase. For the full-year forecast, fiscal year ending April 2027: net sales of 21.0 billion yen, operating income 145.0 million yen, net income attributable to owners of...